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ahe present review aims to summarize relevant studies
ublished during the last year in the field of atherothrom-
osis. A special emphasis was placed on the promotion of
ardiovascular health worldwide, as well as on the need for
progressive shift from the treatment of advanced disease to
arly detection and enhanced prevention.
pidemiology and Public Health Impact
mportant information on the magnitude of the burden of
ardiovascular disease (CVD) became available in 2007.
uring the last 2 decades, coronary heart disease (CHD)
ge-specific death rates fell by 40% in high-income
ountries (1,2). Prolonged survival has translated into grow-
ng disease prevalence and number of hospitalizations, with
uch smaller reductions in absolute mortality and stagger-
ng financial burden: the estimated annual cost of CVD in
he U.S. is $431 billion (1,3). The 1-year incidence of death,
yocardial infarction (MI), stroke, or hospitalization for an
therothrombotic event is 14% for patients with established
therosclerotic disease, and 5% for patients with multiple
2) risk factors, according to an international registry (4).
ith continuing increase in expenditure and progressive
ging of the population, the present healthcare system
ppears unsustainable in the long run (5). The importance
f considering CVD a global health priority was empha-
ized: CVD is the main killer also in low- and middle-
ncome countries, and causes 3 times more deaths than the
ost lethal infectious diseases combined. In developing
ountries, CVD affects younger people of working age and
as additional economic impact (6).
Up to 50% of the reduction in age-adjusted mortality
rom CHD can be attributed to the application of evidence-
ased therapies rather than to effective prevention (1,2,7).
lthough the remaining improvement in survival can be
xplained by reductions in some risk factors, obesity and
iabetes markedly increased, as well as the burden of CVD
ttributable to diabetes (2,8). Of major concern, risk profile
orsened in children and adolescents: hypertension, obesity,
iabetes, and physical inactivity escalated, whereas choles-
erol levels and tobacco use remained unchanged (9). In
rom The Zena and Michael A. Wiener Cardiovascular Institute/Marie-Josee and
enry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine,c
ew York, New York.
Manuscript received November 12, 2007; accepted December 13, 2007.eveloping regions, the prevalence of traditional risk factors
s on the rise in both adults and the young (6). According to
survey in 168,000 primary care patients in 63 countries
orldwide, 60% of men and 50% of women are either
verweight or obese in all regions except southern and
astern Asia (10). Approximately 25% of the world popu-
ation smokes, with two-thirds living in 15 low- and
iddle-income countries (11). Tobacco smoke exposure
as shown to cause dose-dependent endothelial dysfunc-
ion in children (12). Smoking and obesity/inactivity
ave become the 2 leading modifiable causes of prema-
ure death (13).
arly Detection and Risk Assessment
raditional risk factors. Traditional risk factors continued
o be the cornerstone of prevention and risk stratification. A
eport from NHANES (National Health and Nutrition
xamination Survey) estimated that the percentages of
dult Americans falling into the low, moderate, moderate-
o-high, high, and very-high risk categories are 61.1%,
7.2%, 5.4%, 10.6%, and 5.7%, respectively (Fig. 1) (14).
hese findings suggest that the “intermediate-risk” group
ay be smaller than previously thought. The European
ociety of Cardiology updated region-specific charts for
redicting the 10-year risk of a first fatal atherosclerotic
vent based on age, gender, smoking habit, systolic blood
ressure, and total cholesterol (15). In an attempt to
mprove primary prevention worldwide, the World
ealth Organization proposed the use of similar simpli-
ed region-specific charts that also consider the presence
f diabetes (16).
A number of studies evaluated the roles of lipids in
ardiovascular risk. The relationship between age, lipid
rofile, and incident fatal MI was evaluated in 128,000
ubjects followed for a mean of 10.3 years. Most of the
xcess risk associated with age could be attributed to
ong-term exposure to a proatherogenic lipid environment,
hus suggesting that it is potentially modifiable (17). Inde-
endent, long-term associations with MI, CHD, and death
ere also described for nonfasting concentrations of serum
riglycerides in both men and women (18).
Several studies addressed the relationship between obesity
nd CVD. The waist-to-hip ratio was independently asso-
iated with the presence of coronary calcium by computed
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March 4, 2008:944–55 Year in Atherothrombosisomography (CT) and of aortic plaque by magnetic reso-
ance imaging (MRI) (19). The contribution of subclinical
VD to future events in obese individuals was highlighted
n the Framingham Offspring study (20). Both abdominal
isceral and subcutaneous adiposity correlated with markers
f inflammation or oxidative stress (21), reinforcing the
roatherogenic state associated with obesity (Fig. 2) (22).
egarding glucose metabolism, a high dietary glycemic load
as independently associated with increased risk of CHD in
omen (23). Elevated fasting glucose independently pre-
icted heightened CVD mortality in 10,428 Australian
ubjects (24), but this risk was markedly mitigated in the
bsence of the metabolic syndrome in another investigation
ncluding 30,000 Chinese individuals (25). A meta-
nalysis of 37 longitudinal studies and 173,000 patients
eported a relative risk of 1.78 for cardiovascular events and
eath associated with the metabolic syndrome, which re-
ained significant even after adjustment for its individual
omponents (26).
erum biomarkers. Among the many reports published in
007 evaluating the diagnostic and prognostic significance
f numerous biomarkers, several studies deserve special
onsideration. A novel algorithm from the Women’s Health
tudy including C-reactive protein (CRP) and, in diabetic
atients, hemoglobin A1C was developed and validated. It
esulted in reclassification of risk category in 30% to 45% of
ntermediate-risk women, with superior predictive ability
han the NCEP ATP-III (National Cholesterol Education
Figure 1 Distribution of CV Risk
and LDL Levels in American Adults
Absolute numbers of individuals (in millions) for each National Cholesterol Edu-
cation Program Adult Treatment Panel III risk category and level of low-density
lipoprotein cholesterol (LDL-C) are shown. Those meeting the recommended
LDL-C target levels are highlighted in green, those requiring therapeutic
changes are indicated in red, and those in whom therapeutic changes could be
appropriate are shown in yellow. The majority of the population falls into the
low-risk category; however, it is evident that most individuals with the highest
risk do not meet the desired LDL-C goal. CV  cardiovascular. Reprinted, with
permission, from Keevil et al. (14).rogram Adult Treatment Panel III) model (27). Arguinggainst routine CRP measurement, NHANES investigators
stimated that such approach would lead to modification of
he target low-density lipoprotein (LDL) cholesterol only in
.1% of the U.S. adults (28). In elderly participants of the
ardiovascular Health study without manifest CVD, in-
reased levels of CRP were associated with impaired prog-
osis only in patients with subclinical atherosclerosis as
etermined by the carotid intima-media thickness (CIMT)
29). Data from the same study suggested that polymor-
hisms of the CRP gene contribute significantly to both
lasmatic concentrations and cardiovascular risk, but not to
IMT (30).
The strong prognostic implications of increased levels of
-terminal pro-brain natriuretic peptide (BNP) were high-
ighted in 20,000 high-risk individuals from the Heart
rotection study. After an average follow-up of 5 years,
levated N-terminal pro-BNP concentrations indicated
arkedly increased risk of not only heart failure but also
cclusive atherothrombotic events (Fig. 3) (31). Compara-
le independent predictive ability, superior to CRP, was
onfirmed in a population-based study with a median
ollow-up of 9.4 years (32). In participants of the Framing-
am Offspring study in whom multiple markers of inflam-
ation, neurohormonal activity, and endothelial dysfunc-
ion were quantified, increased levels of aldosterone and
lasminogen activator inhibitor-1 were independent predic-
ors of incident metabolic syndrome (33). Additionally, a
reliminary study demonstrated correlations of plasma levels
f beta2-microglobulin with the ankle-brachial index and
unctional capacity, and suggested a potential role specifi-
ally for the diagnosis of peripheral arterial disease (34).
Figure 2 Adipocyte Abnormalities in Obesity
and the Proatherogenic Role of Adiposity
Progressive weight gain leads to adipocyte enlargement and a pro-inflammatory
state with increased macrophage activation, secretion of chemokines and cyto-
kines, and endothelial damage. ER  endoplasmic reticulum; IKK  IkappaB
kinase; IL  interleukin; JNK  c-Jun N-terminal kinase; MCP  monocyte che-
moattractant protein; SAA  serum amyloid A; TLR  toll-like receptor; TNF 
tumor necrosis factor. Reprinted, with permission, from Gustafson et al. (22).
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Year in Atherothrombosis March 4, 2008:944–55Two studies questioned the prognostic value of individual
iomarkers in the general population and suggested some,
lthough modest, additive predictive ability of multimarker
pproaches over conventional risk stratification. Ten bi-
markers were measured in 3,209 patients followed for a
edian of 7.4 years. The adjusted hazard ratio of death was
.08 for the top versus the 2 lower quintiles of a multimar-
er score containing BNP, homocysteine, CRP, renin, and
rinary albumin-to-creatinine ratio; the hazard ratio of
ajor cardiovascular events was 1.84 for a score containing
NP and urinary albumin-to-creatinine ratio (35). In a
econd investigation the ankle-brachial index and 17 bi-
markers were quantified in 1,592 patients followed for a
ean of 17 years. A score including interleukin-6, intercel-
ular adhesion molecule-1, lipoprotein(a), and tissue plas-
inogen activator provided some added value for the
rediction of major cardiovascular events (36).
irculating endothelial progenitor cells and genetic
arkers. There is increasing evidence of the crucial role of
ndothelial progenitor cells in the repair of chronic endo-
helial injury secondary to cardiovascular risk factors. Both
n apparently healthy individuals and in those with CVD
here is an inverse correlation between the number and
unctional activity of endothelial progenitor cells and risk
rofile, indicating a delicate balance between regenerative
apacity and development of disease (37). Enhancing the
umber and function of circulating progenitor cells is,
Figure 3 BNP and CV Risk
Multivariate-adjusted relative risks of various cardiovascular (CV) events accord-
ing to baseline levels of N-terminal (N) pro-brain natriuretic peptide (BNP). CI 
confidence interval. Modified, with permission, from Emberson et al. (31).herefore, an attractive therapeutic target, and promising wreliminary results with peroxisome proliferator-activated
eceptor-gamma agonists (glitazones) were reported (38).
Homozygosity for the haptoglobin 2 gene was associated
ith down-regulation of the hemoglobin scavenger receptor
n diabetic patients, suggesting that inability to clear toxic-
ree hemoglobin from intraplaque hemorrhage may be an
mportant contributor to diabetic risk (39). In an attempt to
alidate previously described genetic risk factors for CVD,
ne investigation tested 85 variants of 70 genes in 811
atients with acute coronary syndromes and 650 control
ubjects. Only one variant in the beta-fibrinogen gene was
arginally different between the groups (40). The inability
o replicate prior associations in different populations high-
ighted the complexity of the interactions between multiple
enetic and environmental factors, and suggests that exten-
ive research will be necessary before the application of
enetic profiling in clinical practice (41). Identification of
eaningful variants will require powerful genotyping tools
nd validation in different populations. One such study
erforming genome-wide analysis compared 500,000
ingle-nucleotide polymorphisms in 2 independent popula-
ions of patients with CHD and control subjects. Of the 7 loci
hat were identified as high-likelihood candidates, the stron-
est association was noted for a region of chromosome 9 that
ncodes genes involved in cell cycle regulation (42). Similar
ultipopulation genome-wide association studies allowed for
he identification of at least 10 loci linked to type 2 diabetes,
ach exerting a modest effect on risk (Fig. 4) (43).
etection of subclinical disease and imaging. In appar-
ntly healthy individuals, the number of imaging tests
evealing extensive atherosclerosis correlated with the Fra-
ingham score. However, there were frequent discrepancies
etween estimated risk and disease burden (Fig. 5) and
ifferent modalities agreed poorly with one another, high-
ighting the challenge of inferring information of one
ascular bed from the status of another (44). Several studies
ddressed the prognostic implications of detecting subclin-
cal disease in the general population. A multicenter trial
andomized67,000 men of age 65 to 74 years to receive or
ot an invitation for ultrasonographic screening of abdom-
nal aneurysm. After a mean follow-up of 7.1 years,
neurysm-related mortality was halved in the group invited
or screening, an approach that additionally proved highly
ost-effective (45). According to a meta-analysis of 8 studies
nrolling 31,000 individuals, the age- and gender-
djusted hazard ratios of 0.1 mm increment in common
IMT were 1.15 and 1.18, respectively, for incident MI
nd stroke (46). The presence of occlusive and sub-occlusive
eripheral arterial disease independently predicted MI and
eath in 1,325 individuals in whom the ankle-brachial index
nd carotid and femoral plaques by ultrasound were evalu-
ted (47). Additionally, in 117 patients with prior stroke or
ransient ischemic attack and serial transesophageal echo-
ardiograms, progression of aortic atheroma over 12 months
as associated with an almost 6-fold increase in risk of
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March 4, 2008:944–55 Year in Atherothrombosisubsequent cardiovascular events during a median follow-up
f 1.7 years (48).
The field of cardiac CT was particularly active. A new
xpert consensus document emphasized the incremental
redictive value of calcium scoring over conventional risk
actors for the occurrence of cardiovascular death or MI in
symptomatic individuals, particular those at intermediate
Figure 4 Genetic Risk of T2D
The risk of type 2 diabetes (T2D) is estimated from a logistic regression model
containing 10 susceptibility genetic variants. The x axis contains 20 equal
intervals of predicted T2D risk derived from the model. The y axis shows the
number (with 95% confidence limits) of T2D cases within each predicted risk
interval. The horizontal dashed line indicates the sample prevalence of T2D.
There is a 4-fold increase in risk of T2D (from 5% to 20%) from the lowest to
the highest predicted risk categories. Modified, with permission, from Scott et
al. (43). Reprinted with permission from AAAS.
Figure 5 Distribution of Atherosclerotic Burden According to B
Proportions of male (A) or female (B) subjects with high atherosclerotic burden (d
cal disease: carotid intima-media thickness, magnetic resonance imaging-derived a
grouped according to their Framingham risk score. Modified, with permission, fromisk (49). This prognostic ability was reiterated in the largest
eries available so far (25,000 patients followed for 6.8 
years), which showed markedly reduced adjusted survival
ith increasing calcium scores (50), a risk that may be
odulated by the presence of concomitant ischemia (51).
amily history was shown to contribute to both develop-
ent and progression of coronary calcification (52). Con-
ersely, the influence of environmental factors was high-
ighted by the positive association between the calcium score
nd air pollution (53). Regarding contrast-enhanced coro-
ary CT angiography, a study of 254 patients with chest
ain suggested that CT is useful in subjects with low or
ntermediate pre-test probability, in whom a normal scan
eliably rules out disease and a positive result should prompt
dditional testing (54). Importantly, CT was able to detect
therosclerosis, including calcified and non-calcified non-
tenotic plaques, in 50% of the segments considered
ormal by invasive catheterization (55). Computed tomog-
aphy is more accurate for the evaluation of plaques in the
roximal coronary segments, the most common location for
hin-cap fibroatheromas and plaque ruptures as confirmed
n a recent autopsy series (56). The prognostic value of CT
oronary angiography was highlighted in a retrospective
tudy of 1,127 symptomatic individuals. Besides stenosis
everity and proximal disease location, the presence of 5
egments with any detectable plaque was identified as an
ndependent predictor of all-cause mortality in multivariate
nalysis. Survival in the absence of plaque in the left main or
eft anterior descending arteries surpassed 97% after an
verage follow-up of 15 months (57).
Black-blood MRI for noninvasive plaque quantification
n the coronary arteries and the aorta was employed in
nother investigation of type 1 diabetes mellitus. Aortic
laque extent was similar in patients with or without
ephropathy, but the former had significantly increased
oronary disease burden (Fig. 6), which additionally corre-
ated with diabetes duration and total cholesterol level (58).
e Risk
as value 80th percentile) in 0, 1, 2, 3, or 4 tests for the presence of subclini-
laque burden, aortic calcium score, and coronary calcium score. Patients are
resan et al. (44).aselin
efined
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Year in Atherothrombosis March 4, 2008:944–55he degree of vascular inflammation assessed with com-
ined CT and 18F-fluorodeoxyglucose positron emission
omography was significantly correlated with the number of
omponents of the metabolic syndrome (59). Another
nvestigation reported excellent interobserver, intraobserver,
nd interscan reproducibility of this technique (Fig. 7),
uggesting a potential role for serial testing (60). In this
egard, reductions of vessel wall inflammation after statin
herapy could be demonstrated (61). Using intravascular
ltrasound (IVUS), it was shown that the progression/
egression in atheroma volume in response to interventions
s inversely correlated to the amount of calcification, sug-
esting that calcified plaques are more resistant to change
62). Optical coherence tomography, an alternative invasive
odality with superb spatial resolution, demonstrated su-
erior ability than IVUS or coronary angiography for the
etection of plaque rupture/erosion or intracoronary throm-
us in patients with acute MI (63).
In the field of molecular imaging, successful detection of
laque inflammation with MRI was possible with
adolinium-loaded micelles coupled with antibodies against
he macrophage scavenger receptor (64). An alternative
pproach used CT and a novel iodinated nanoparticulate
Figure 6 MRI-Derived Coronary Plaque Burden
Bright-blood (A and C) and black-blood (B and D) magnetic resonance imaging (M
minuria (top) and a second patient with diabetic nephropathy (bottom). Both patie
increased in the patient with nephropathy (D, black arrows) in comparison with th
Kim et al. (58).ontrast that is selectively taken up by macrophages to buccessfully detect experimental aortic atherosclerosis (Fig.
) (65). Vascular inflammation in various stages of athero-
clerosis could be depicted using ultrasound and micro-
ubbles targeted to vascular cell adhesion molecule-1 in
ice (66). In addition, an intraoperative near-infrared
uorescence imaging system and the injection of platelets
abeled with a novel fluorophore allowed for the detection of
cclusive and nonocclusive thrombi in porcine carotid,
emoral, and coronary arteries in vivo (67).
herapy
isk factor management and importance of medical
herapy. Reinforcing the relevance of early identification of
isk factors, the American Heart Association released rec-
mmendations for primary prevention in children and
dolescents (9). Dietary counseling starting at infancy and
aintained throughout childhood resulted in maintained
ecreases in total and LDL cholesterol until at least 14 years
f age (68). Approximately 34% of American adults have
DL cholesterol levels above the recommended goal, and
he number is 75% in those with the highest risk.
oreover, in almost 50%, lower LDL concentrations would
he right coronary artery (RCA) in a patient with type 1 diabetes and normoalbu-
ve a patent RCA lumen; however, the thickness of the vessel wall is markedly
nt with normoalbuminuria (B, white arrows). Reproduced, with permission, fromRI) of t
nts ha
e patiee desirable (Fig. 1) (14). Moderate-to-high levels of
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March 4, 2008:944–55 Year in Atherothrombosishysical activity in daily tasks were associated with decreases
n coronary events across the spectrum of baseline cardio-
ascular risk (69). In addition, it was estimated that a 20%
ecrease in the number of world smokers by 2020 could
revent 100 million premature deaths (11).
One of the highlights of 2007 was the publication of the
OURAGE (Clinical Outcomes Utilizing Revasculariza-
ion and Aggressive Drug Evaluation) trial. Of 35,000
otential candidates, 2,287 patients with stable coronary
isease, objective mild/moderate ischemia, and proven se-
ere coronary stenoses were randomized to optimized med-
cal therapy with or without percutaneous intervention
using mainly bare-metal stents). Of note, 58% of the
atients had class II/III angina and 69% multivessel disease,
ncluding significant stenosis of the proximal left anterior
escending artery in30%. After a median follow-up of 4.6
ears, there were no significant differences between the 2
roups in rates of death, MI, stroke, or their combination
Table 1). Patients initially assigned to percutaneous inter-
ention had lower rates of subsequent revascularization and
ngina, although symptoms decreased significantly in both
roups (70). The results of this trial did not come without
riticism (71), but overall reinforced the importance of
ggressive medical management. Comparable findings came
rom MASS (Medicine, Angioplasty, or Surgery Study) II,
hich reported similar 5-year mortality for percutaneous
ntervention, coronary bypass surgery, or medical therapy as
he treatment of stable patients with multivessel coronary
Figure 7 Vascular Inflammation Demonstrated With PET/CT
Sagittal images of the chest obtained with computed tomography (CT) (left), p
(PET/CT) (right). The top row shows the baseline scan and the bottom row a
glucose in the aortic arch (arrows) can be noted in both scans. A  anterior; Pisease and preserved ejection fraction, although revascular- szation provided better symptomatic control (72). Addition-
lly, adherence to therapies of proven benefit was indepen-
ently associated with improved post-MI survival (73).
owever, the results of the third EUROASPIRE (Euro-
ean Action on Secondary Prevention through Intervention
o Reduce Events-III) survey demonstrated that large pro-
ortions of patients with known CHD remain undertreated
74).
ipid therapy. A long-term follow-up of 5,778 men with-
ut previous MI enrolled in WOSCOPS (West of Scotland
oronary Prevention Study), which compared pravastatin
ersus placebo for 5 years, revealed ongoing protection from
HD death and nonfatal MI during an average follow-up
f up to 10 years after conclusion of the trial (75). Several
tudies addressed intensive lipid-lowering therapy. Treat-
ent with rosuvastatin 40 mg (previously reported to cause
oronary plaque regression in high-risk patients) to a mean
DL concentration of 78 mg/dl was associated with slowed
IMT progression in low-risk individuals (76). Another
nvestigation demonstrated maintained survival benefits of
tatin therapy in those subjects with very low LDL levels
60 mg/dl) (77). A meta-analysis of 6 trials enrolling
28,000 subjects reported a decrease in major cardiovascu-
ar events with intensive statin therapy in patients with
ither unstable or stable disease, but reductions in all-cause
ortality only in the former (78). Accordingly, cost-
ffectiveness of routine high-dose statins was high in the
ontext of acute coronary syndromes but questionable for
emission tomography (PET) (middle), and the corresponding fused images
up study performed 2 weeks later. Reproducible uptake of 18F-fluorodeoxy-
sterior. Reproduced, with permission, from Rudd et al. (60).ositron
follow-
 potable patients (79).
m
o
(
a
p
1

b
c
w
C
T
5
i
b
c
H
L
s
i
l
r
1
o
a
i
t
d
i
i
I
t
p
d
I
(
t
o
d
A
u
r
r
I
o
a
p
c
a
fi
e
d
p
d
t
(
A
C
R
a
a
t
(
i
a
I
P
950 Sanz et al. JACC Vol. 51, No. 9, 2008
Year in Atherothrombosis March 4, 2008:944–55Current guidelines for cardiovascular prevention focus
ainly on LDL cholesterol, but evidence has accumulated
n the growing importance of high-density lipoprotein
HDL) cholesterol as a therapeutic target. A post-hoc
nalysis of 4 trials performing serial coronary IVUS in 1,455
atients with baseline LDL and HDL concentrations of
24 and 45.1 mg/dl, respectively, reported that regression
5% in atheroma volume occurred if LDL levels decreased
elow 87.5 mg/dl and HDL increased by 7.5% (80). The
linical relevance of small changes in HDL cholesterol levels
ith statin therapy was highlighted in a sub-analysis of
HD patients enrolled in the TNT (Treating to New
Figure 8 Molecular Imaging of Macrophages
With the Iodinated Contrast Agent N1177
Intracytoplasmic dark granules corresponding to the contrast agent can be
noted after incubation of macrophages in vitro with N1177 (A). (B to D) Corre-
spond to in-vivo axial computed tomographic images of the abdominal aorta
(arrowheads) in atherosclerotic rabbits obtained before (B), during (C), and
2 h after the administration of N1177 (D). Late, selective enhancement of the
vessel wall can be noted (D). (E) Demonstrates the regions of high macro-
phage density in red (arrow) superimposed on the aortic angiography. Modi-
fied, with permission, from Hyafil et al. (65).argets) trial that demonstrated a 1.1% reduction in the c-year risk of major cardiovascular events per 1 mg/dl
ncrement in HDL concentration (81). Importantly, this
eneficial effect persisted after adjustment for multiple
ovariates and in subjects with very low LDL levels (Fig. 9).
owever, the ILLUMINATE (Investigation of Lipid
evel Management to Understand Its Impact in Athero-
clerotic Events) trial was prematurely stopped because of
ncreased mortality associated with torcetrapib, a cho-
esterylester transfer protein inhibitor with potent HDL-
aising properties. The ILLUMINATE trial randomized
5,067 patients with high-risk (defined as a history of CVD
r diabetes) to atorvastatin (to a target LDL 100 mg/dl)
lone or in combination with torcetrapib. Despite the 72%
ncrement in HDL and 25% reduction in LDL levels, the
orcetrapib arm experienced a 25% increase in major car-
iovascular events (6.2% vs. 5%, p  0.001) and a 58%
ncrease in total mortality (1.2% vs. 0.8%, p 0.006), which
ncluded cardiovascular and noncardiovascular causes (82).
maging studies shed further light on potential reasons for
he failure of torcetrapib: when evaluating the 2-year rate
rogression of atherosclerotic burden, no effect could be
etected with either carotid ultrasound (83,84) or coronary
VUS (85). Post-hoc analyses of the ILLUMINATE trial
82) raised the hypothesis that the deleterious effects of
orcetrapib may be secondary, at least in part, to activation
f the renin-angiotensin-aldosterone system rather than to
ysfunctional HDL, although further research is warranted.
n alternative approach to augment HDL levels was eval-
ated in 187 patients with acute coronary syndromes,
andomized to receive 4 weekly infusions of placebo or
ecombinant HDL containing wild-type apoA-I. Serial
VUS demonstrated a 1.6% reduction in percentage ather-
ma volume for the placebo group and 3.4% for the active
rm (significant vs. baseline but not in comparison with
lacebo). However, there were significant changes in plaque
haracteristics and luminal narrowing that suggested favor-
ble effects of HDL (86). In agreement with these
ndings, 2 infusions of exogenous apoA-IMilano in
xperimentally induced atherosclerosis caused not only
isease regression but also a shift to a more stable plaque
henotype as evidenced by reductions in macrophage
ensity and expression of matrix metalloproteinase-2,
issue factor, or monocyte chemoattractant protein-1
87).
ntithrombotic therapy. A post-hoc analysis of the
HARISMA (Clopidogrel for High Atherothrombotic
isk and Ischemic Stabilization, Management, and Avoid-
nce) trial suggested that dual antiplatelet therapy with
spirin and clopidogrel may be superior to aspirin alone in
he subgroup of symptomatic patients with highest risk
defined as documented peripheral arterial disease, MI, or
schemic stroke) (88). Improved dual antithrombotic ther-
py was evaluated in TRITON-TIMI (Trial to Assess
mprovement in Therapeutic Outcomes by Optimizing
latelet Inhibition with Prasugrel-Thrombolysis In Myo-
ardial Infarction)-38. Prasugrel, a novel thienopyridine
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March 4, 2008:944–55 Year in Atherothrombosisith more potent, rapid and consistent antiplatelet effects,
as compared with clopidogrel in 13,608 patients with
cute coronary syndromes undergoing percutaneous coro-
Figure 9 CV Risk and HDL
Multivariate-adjusted risk of major cardiovascular (CV) events across different
quintiles (Q) of high-density lipoprotein (HDL) cholesterol levels in 9,770 coro-
nary heart disease patients (A) and in the subgroup with low-density lipopro-
tein cholesterol 70 mg/dl (B). Abbreviations as in Figure 3. Modified, with
permission, from Barter et al. (81).
ummary Outcomes in the COURAGE Trial
Table 1 Summary Outcomes in the COURAGE Trial
Outcome PCI (n  1,149)
Death and nonfatal MI 19%
Death, MI, and stroke 20%
Hospitalization for acute coronary syndrome 12.4%
Death 7.6%
Nonfatal MI 13.2%
Revascularization 21.1%
I  confidence interval; COURAGE  Clinical Outcomes Utilizing Revascularization and Aggressivaary intervention. After a median follow-up of 15 months,
rasugrel resulted in a 19% relative reduction in the risk of
he primary efficacy end point, at the expense of a 32%
elative increase in major bleeding (Fig. 10). Considering
oth end points, there was a net clinical benefit of prasugrel
hazard ratio 0.87; p  0.004) (89). Other important
dvances in antithrombotic therapy of acute coronary syn-
romes (addressed in other issues of this series) included
irect thrombin inhibitors (bivalirudin) and factor Xa in-
ibitors (fondaparinux) (90,91). In the specific group of
atients with peripheral arterial disease, the addition of oral
nticoagulation to standard antiplatelet therapy increased
he risk of life-threatening bleeding and did not prevent
ajor cardiovascular events (92).
VD and diabetes. The communication of potentially
armful cardiovascular effects of thiazolidinediones trig-
ered one of the most heated debates in 2007. A post-hoc
eta-analysis of 42 trials comparing rosiglitazone (n 
5,565) with other oral antidiabetic drugs or placebo (n 
2,282) reported an odds ratio of 1.43 for MI (p  0.03),
nd of 1.64 for cardiovascular death (p  0.06) (93). The
imitations of this analysis were quickly pointed out: inclu-
ion of short-term, heterogeneous studies; inconsistent out-
ome adjudication; small absolute numbers of events; or use
f trial summary results rather than patient-level data (94).
epeated analysis of the same studies with different statis-
ical methodology yielded lower, nonsignificant odds ratios
95). However, a more restringing meta-analysis of only
andomized trials that evaluated pre-specified, indepen-
ently adjudicated outcomes in type 2 diabetes (n 14,291)
ound a similar 42% increase in the risk of MI and doubled
isk of heart failure, but not of cardiovascular mortality (96).
he debate prompted an interim analysis of the ongoing,
ulticenter RECORD (Rosiglitazone Evaluated for Car-
iac Outcomes and Regulation of Glycemia in Diabetes)
rial, specifically designed to test the drug’s cardiovascular
afety. The increase in adverse outcomes associated with
osiglitazone could not be confirmed (with the exception of
eart failure) although insufficient power at that point
recluded reaching firm conclusions (97). Moreover, a large
bservational study in 160,000 individuals failed to detect
igher rates of MI (98). The Food and Drug Administra-
ion’s final decision was to keep rosiglitazone in the market
ical Therapy (n  1,138) Hazard Ratio (95% CI) p Value
18.5% 1.05 (0.87–1.27) 0.62
19.5% 1.05 (0.87–1.27) 0.62
11.8% 1.07 (0.84–1.37) 0.56
8.3% 0.87 (0.65–1.16) 0.38
12.3% 1.13 (0.89–1.43) 0.33
32.6% 0.60 (0.51–0.71) 0.001
Evaluation; MI  myocardial infarction; PCI  percutaneous coronary intervention.Meddding a label warning of increased risk of heart failure and
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Year in Atherothrombosis March 4, 2008:944–55otentially also of myocardial ischemia, particularly in pa-
ients taking insulin or nitrates (99). To address whether
hese effects are drug or class specific, a subsequent meta-
nalysis of 19 randomized controlled trials testing pioglita-
one (n  16,390) showed overall protective cardiovascular
nfluence (18% reduction in the combined end point of
eath, MI, or stroke) that might be explained by the more
avorable lipid profile changes induced by pioglitazone in
omparison with rosiglitazone (100).
Finally, the ADVANCE (Action in Diabetes and Vas-
ular disease: preterAx and diamicroN-MR Controlled
valuation) trial (101) randomized 11,000 patients with
ype 2 diabetes plus other risk factors or established CVD to
lacebo or a fixed combination of perindopril and indap-
mide (regardless of the presence of hypertension or use of
ntihypertensive drugs). After a mean follow-up of 4.3
ears, the active arm experienced a significant 9% reduction
n a composite end point of major macro- and microvascular
omplications and an 18% reduction in cardiovascular
eath, which might be due to the lower blood pressure
chieved with the combination therapy.
onclusions
umerous advances in atherothrombosis took place in
007, including prevention and promotion of health, bio-
maging, and genetics. Antiatherosclerotic therapies were
articularly put to the test: the importance of intensive
edical management (COURAGE), the failure of torce-
rapib (ILLUMINATE), the still controversial future of
osiglitazone, and novel antithrombotic drugs like prasugrel
Figure 10 Efficacy and Safety of Prasugrel Versus Clopidogrel i
Cumulative rates of the primary efficacy end point (cardiovascular death, nonfatal
(Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhib
nary syndromes; CI  confidence interval. Modified, with permission, from Wiviottonstituted the highlights of an active and exciting year.eprint requests and correspondence: Dr. Valentin Fuster,
ardiovascular Institute, Mount Sinai Hospital, One Gustave L.
evy Place, Box 1030, New York, New York 10029. E-mail:
alentin.fuster@mssm.edu.
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